Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to dissemintate knowledge & skills of Acute Cardiovascular Care
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission: To promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our goal is to reduce the burden in cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our Mission is "to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death"
To improve quality of life and logevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
Working Groups goals is to stimulate and disseminate scientific knowledge in different fields of cardiology.
ESC Councils goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. David Holmes,
Prof. Carlo Di Mario,
Presenter | see Discussant report
Carlo Di Mario
Access to the congress content with ESC Congress 365
The Transcatheter Valve Treatment Sentinel Pilot Registry is a prospective independent consecutive collection of individual patient data entered into a web-based case record form (CRF) or transferred from compatible national registries. A total of 4571 patients underwent transcatheter aortic valve implantation (TAVI) between January 2011 and May 2012 in 137 centres of 10 European countries. Average age was 81.4±7.1 years with equal representation of the two sexes. Patients ≤80 had greater incidence of diabetes, COPD, extracardiac arteriopathy, dialysis, previous myocardial infarction, previous cardiac surgery or PCI, previous aortic valve replacement (AVR), LVEF <30%. Logistic Euroscore (20.2±13.3), access site (femoral approach preferred in 74.2%), type of anesthesia (only local used in 39.0% of transfemoral procedures) and duration of hospital stay (9.3±8.1 days) showed wide variations among the participating countries. In-hospital mortality (7.4%), stroke (1.8%), myocardial infarction (0.9%), major vascular complications (3.1%) were similar in the balloon expandable SapienXT and the self-expandable CoreValve, p=0.15. Mortality was lower in trans-femoral (5.9%) than in trans-apical (12.8%) and other access routes (9.7%), p<0.01. Advanced age, high logistic Euroscore, pre-procedural ≥grade2 mitral regurgitation, deployment failure predicted higher mortality at multivariate analysis. A permanent pace-maker was required in 23.4% of CoreValves and 6.0% of SapienXT valves, p<0.01. Echocardiography showed postprocedural aortic regurgitation grade 2 in 7.7% and grade 3 in 1.3% (Grade≥2 11.4% CoreValve and 6.7% SapienXT, p<0.01). This truly contemporary TAVI registry using the most recent valve types and delivery catheters suggests lower mortality, stroke and vascular complications than historical studies and registries.
Discussant | see Presenter abstract
711007 - 711008
Clinical Trial & Registry Update III: Updates on Atrial Fibrillation and Valves
© 2016 European Society of Cardiology. All rights reserved